Search...
Key facts: Eli Lilly co-develops ELUNATE®; Endowment sells 162,693 shares
I'm PortAI, I can summarize articles.
Eli Lilly is co-developing fruquintinib, branded as ELUNATE®, with HUTCHMED in China. The drug will be featured at the 2025 ESMO Asia Congress and ASH Annual Meeting.1Lilly Endowment Inc sold 162,693 shares of Eli Lilly (LLY) for about $178.4 million in two transactions. They now hold 92,196,978 shares.2
- Eli Lilly is co-developing fruquintinib, branded as ELUNATE®, with HUTCHMED in China. The drug will be featured at the 2025 ESMO Asia Congress and ASH Annual Meeting.1
- Lilly Endowment Inc sold 162,693 shares of Eli Lilly (LLY) for about $178.4 million in two transactions. They now hold 92,196,978 shares.2
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments